-transparent.png){kind=logo}
1. Plasma levels of 5-fluorouracil (5FU) have been determined in eleven cancer patients after 0.5 g and 1.0 g intravenous doses, and in one patient after paired 1.0 g oral and intravenous doses. 2. The plasma half-life after the 0.5 g intravenous dose was relatively constant, irrespective of the stage and spread of the disease. 3. Plasma kinetics of the drug were dose dependent. Doubling of the intravenous dose produced a 1.5-fold increase in plasma half life, a two-fold increase in initial plasma drug concentration, and a three-fold increase in area under the concentration/time curve. 4. In one patient receiving paired 1.0 g intravenous and oral doses nine weeks apart, an increase in the bioavailability of the drug coincided with a marked clinical regression in palpable intra-abdominal metastases. 5. The significance of measuring plasma drug kinetics and their relationship to drug efficacy and toxicity are discussed.
R E Finch, and
M R Bending, and
A F Lant
May 1984,
Gan to kagaku ryoho. Cancer & chemotherapy,
R E Finch, and
M R Bending, and
A F Lant
December 1978,
European journal of clinical pharmacology,
R E Finch, and
M R Bending, and
A F Lant
May 1980,
Acta pharmacologica et toxicologica,
R E Finch, and
M R Bending, and
A F Lant
July 1964,
Archives internationales de pharmacodynamie et de therapie,
R E Finch, and
M R Bending, and
A F Lant
January 1982,
Cancer chemotherapy and pharmacology,
R E Finch, and
M R Bending, and
A F Lant
October 1971,
Cancer,
R E Finch, and
M R Bending, and
A F Lant
February 1981,
NIDA research monograph,
R E Finch, and
M R Bending, and
A F Lant
May 1991,
Gan to kagaku ryoho. Cancer & chemotherapy,
R E Finch, and
M R Bending, and
A F Lant
June 1985,
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
R E Finch, and
M R Bending, and
A F Lant
May 1990,
Hinyokika kiyo. Acta urologica Japonica,
